OncoMatch

OncoMatch/Clinical Trials/NCT06933394

Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma

Is NCT06933394 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Arsenic trioxide and MAPK inhibitors for neuroblastoma.

Phase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06933394Data as of May 2026

Treatment: Arsenic trioxide · MAPK inhibitors · ChemotherapyThis prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of the combination therapy involving arsenic trioxide, MAPK inhibitors, and chemotherapy for stage 4/M neuroblastoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroblastoma

Disease stage

Required: Stage INRG M, INSS STAGE 4

Metastatic disease required

Preoperative staging as INRG M stage or postoperative staging as INSS stage 4 (regardless of risk classification).

Prior therapy

Cannot have received: chemotherapy and abdominal radiation therapy

Lab requirements

Kidney function

glomerular filtration rate (GFR) < 30 ml/(min·1.73 m²) or serum creatinine > 5 mg/dL (442 μmol/L) [excluded]

Liver function

aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≥ 5× upper limit of normal (ULN), or serum total bilirubin ≥ 3× ULN [excluded]

Cardiac function

NYHA heart function class III or IV, or left ventricular ejection fraction (LVEF) < 50% [excluded]

Severe progressive or persistent heart failure: NYHA heart function class III or IV, or left ventricular ejection fraction (LVEF) < 50%. Severe progressive or persistent renal failure: glomerular filtration rate (GFR) < 30 ml/(min·1.73 m²) or serum creatinine > 5 mg/dL (442 μmol/L). Severe liver dysfunction: aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≥ 5× upper limit of normal (ULN), or serum total bilirubin ≥ 3× ULN.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify